Loading the company…
Loading the company…
In the last ten years FDA made 1 decision for Solventum (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (1). The latest was on 2025-10-10.
| Family | Decisions on record |
|---|---|
| Skin substitutes & wound grafts | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2025-10-10 | 510(k) | K251866 | Tegaderm Post-Op Transparent Antimicrobial Dressing |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Solventum.
In 2025, Solventum reported engagement with 20,620 surgeons and other clinicians in the states MedaRep covers, worth $3.5M in consulting, speaking, meals and travel for its device products, the most in California ($505K to 1,953). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($505K, 1,953 engaged), New York ($309K, 1,457 engaged), Texas ($291K, 1,551 engaged), Ohio ($273K, 762 engaged), Florida ($252K, 1,514 engaged).